Gilead Sciences (NASDAQ:GILD) has discontinued a Phase 1 trial for GS-1219, a long-acting subcutaneously delivered treatment ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best ...

Just over a year ago, the European Union and the US Food and Drug Administration approved a new anti-retroviral drug to treat human immunodeficiency virus (HIV) infections. Lenacapavir is the first ...

Despite the success of protease and reverse transcriptase inhibitors, new drugs to suppress HIV-1 replication are still needed. Several other early events in the viral life cycle (stages before the ...

There were still 32,000 new cases of HIV in the U.S. in 2022. And about thousands of people still die annually from AIDS. HIV ...

We might be a step closer to curing HIV, as researchers have developed a way to knock out a version of the virus lurking in the body. Using something called an HIV-like particle (HLP)—which are dead ...

More than 40 years of AIDS research has led to significant advancements in treatment and prevention. Drugs to treat the infection continued to improve, as did patient outcomes. But now there's another ...